shanghai henlius biotech pipeline

Therapeutic Area: Oncology History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Synergising our Innovation centres in China and the US, we continue the momentum for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. The Phase 2 IND application of serplulimab in combination with HLX07 for the treatment of solid tumours was granted by the NMPA. Hengenix is affiliated with Shanghai Henlius Biotech (), a top biopharma company in China co-founded in 2009 by two American biopharmaceutical veterans (Dr. Scott Liu and Dr. Weidong Jiang). Pipeline Drugs is equipped to facilitate both qualitative and quantitative analysis. It demonstrated favorable safety and tolerability profile in a The second product HANQUYOU (trastuzumab, Zercepac in the EUTrade names in Australia: Tuzucip and Trastucip) is the first Chinese mAb biosimilar approved both in the EU and China, bringing more treatment options to patients with HER2 positive breast and gastric cancer worldwide. Xuhui Facility is certificated by China and the EU Good Manufacturing Practice (GMP). Pipeline Prospector delivers free access to a database of Infections and Infectious Diseases drugs under clinical trials which made headlines done by Shanghai Henlius . Pipeline Prospector delivers free access to a database of Immunology drugs under clinical trials which made headlines done by Shanghai Henlius Biotech Henlix, Taiwan. Itis a humanised IgG1 monoclonal antibody injection henlius' diverse pipeline of over 20 innovative monoclonal antibodies (mab) includes (hlx01, rituximab injection, the first commercially launched biosimilar in china), (hlx02, trastuzumab injection, zercepac in the eu, first chinese mab biosimilar approved in both eu and china), 2 products under nda review, and over 20 clinical studies It has been approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors and squamous non-small cell lung cancer (sqNSCLC). September 29, 2022. (. ) shanghai, feb. 18, 2020 /prnewswire/ -- shanghai henlius biotech, inc. (2696.hk, henlius), a global biologics company specialized in the discovery and development of high-quality and. Our commercial capacity totals 48,000L for now with an estimate of 144,000L in 2026. Expansive offering allow users to identify drugs by a wide range of characteristics and features ranging from a geography, company to a specific drug. Research Progress. Phase 3 clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. It develops medicines primarily for oncology, autoimmune and ophthalmic diseases. United States. April 07, 2022. (SPACs), Transportation, Infrastructure & Logistics. Antibody Injection. was granted IND approvals to be evaluated in clinical trials in China and the Shanghai Henlius Biotech, Inc. Henlius established in 2010 is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines to patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. In addition to 5 products and 15 indications launched commercially and 4 NDAs accepted for review, Henlius has conducted over 20 clinical studies for 13 products and 11 immuno-oncology combination therapies worldwide. Two monotherapies and nine immuo-oncology combination therapies clinical trials with HLX10 are ongoing in Henlius pipeline. The results of this study demonstrated the good safety and tolerability of HLX22. Its commercialisation rights in China has been licensed out. Recombinant Anti-RANKL Human Monoclonal cetuximab biosimilar, is mainly for the treatment of mCRC and SCCHN. September 28, 2022. adjuvant treatment of melanoma, RCC, and microsatellite instability-high or mismatch repair deficientmCRC. Our commercial capacity totals 48,000L for now with an estimate of 144,000L in 2026. With this license agreement of the anti-TROP2 antibodies, Henlius' product pipeline will be further expanded. It demonstrated favorable safety and tolerability profile in a patient was dosed in a Phase 1 clinical trial in China. Phase 1 clinical HLX12. Recombinant Anti-Epidermal Growth Factor Receptor (. ) Organon, Deal Size: $103.0 million Henlius is headquartered in Shanghai, China. IT Client Prospector provides intelligence on Shanghai Henlius Biotech Incs likely spend across technology areas enabling you to understand the digital strategy. ramucirumab biosimilar, is for the treatment of advanced GC,mNSCLC and mCRC. Recombinant Anti-Vascular Endothelial Growth Factor Receptor-2 Henlius is headquartered in Shanghai, China. HLX11, Recombinant Anti-HER2 Domain II Humanised Monoclonal Antibody Injection, a pertuzumab biosimilar. June 13, 2022. Pre-clinical studies have shown that HLX07 binds EGFR with similar affinity and has better bioactivity compared to cetuximab. Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. China's streamlined system for biologics approvals has enabled Shanghai Henlius Biotech to bring biosimilars to market faster and potentially at a lower cost, Ping Cao, vice president of Business Development, explains. It Copyright 2019 Shanghai Henlius Biotech, Inc. All rights reserved. Recombinant Anti- Endothelial Growth Factor Receptor (. ) Identify which of Shanghai Henlius Biotech Incs products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. Songjiang First Plant is certificated by China GMP and the EU QP. HLX22. In January, the company announced the first subject was dosed in a Phase 2 clinical trial (NCT04976647) of serplulimab, a novel anti-PD-1 monoclonal antibody (mAb). 1289 Yishan Road, Xuhui District, Shanghai, 200233 Website www.henlius.com Telephone 86 21 33395800 No of Employees 2,933 Industry Pharmaceuticals and Healthcare Ticker Symbol & Exchange 2696 (HKG) Revenue (2021) $260.9M 186.3% (2021 vs 2020) EPS XXX Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content. Its commercialisation rights in China has been licensed out. HLX15 is treatment of postmenopausal women with OP at high risk for fracture. Shanghai, China, Nov, 1st, 2022 - Shanghai Henlius Biotech, Inc. (2696. treatment of postmenopausal women with OP at high risk for fracture. The company operates research and development centers in Shanghai, China, and California, the US. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. SHANGHAI, China I March, 31, 2020 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that HLX07, a recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody (mAb) injection, demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 clinical study (HLX07FIH, NCT02648490) for the treatment of advanced solid tumours. This contains focused and comprehensive coverage of pharmaceuticals in development, an exhaustive resource for the users. anti-LAG-3 human monoclonal antibody injection, is an innovative monoclonal HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) . Access more premium companies when you subscribe to Explorer, China (incl Hong Kong): Companies by Revenue, Building C, No. patient was dosed in a Phase 1 clinical trial in China. Founded in 2010 and headquartered in Shanghai with two R&D centers in Taipei and California, Henlius has established and continues to expand its comprehensive product pipeline of biosimilars and bio-innovative drugs to treat tumors and autoimmune diseases. Product Name: HLX10, Highest Development Status: Phase III Clinical Trial. Have you found what you were looking for? In addition to 5 products and 15 indications launched commercially and 4 NDAs accepted for review, Henlius has conducted over 20 clinical studies for 13 products and 11 immuno-oncology combination therapies worldwide. Fully Human Anti-CTLA-4 Monoclonal Antibody, an ipilimumab biosimilar, can be HLX15. Pipeline Drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. HLX10 (Serplulimab) in combination with chemotherapy showed a significant improvement in OS against chemotherapy, which met the pre-defined efficacy criteria, with good safety and no detection of a new safety signal. The board of directors of Shanghai Henlius Biotech, Inc. announced that on 25 November 2020, the Company entered into a license and co-development agreement with Binacea pharma Inc. , pursuant to. Tumour response was Phase 1 clinical Shanghai Henlius Biotech Profile and History. Henlius has 4 products launched in China, 1 in the European Union (EU). (mNSCLC), Recombinant Anti-LAG-3 Human Monoclonal Antibody Injection, Recombinant Humanized Anti-EGFR and Anti-4-1BB Bispecific Antibody, Recombinant Anti-PDL1 and Anti-TIGIT Bispecific Antibody. potentially used in the treatment of unresectable or metastatic melanoma, Track drug and patent expiries along with geographies impacted. researched and developed as biobetter, is for the treatment of solid tumors. Antibody Injection, a denosumab biosimilar, is potentially indicated for the metastatic esophageal squamous-cell carcinomas (mESCC), extensive-stage small cell lung cancer (ES-SCLC), wet age-related macular degeneration (wAMD), Solid tumours (non-small cell lung cancer, esophageal carcinoma, etc. checkpoint receptor and is regarded as a new generation of immunotherapy target Serplulimab,Carboplatin, Therapeutic Area: Oncology . non-squamous, non-small cell lung cancer (nsNSCLC). We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 450 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide. Lead Product(s): Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval. potentially used in the treatment of unresectable or metastatic melanoma, It is for the treatment of SCCHN. NCT02648490) for the treatment of advanced solid tumours. researched and developed as biobetter, is for the treatment of solid tumors. Copyright 2019 Shanghai Henlius Biotech, Inc. All rights reserved. The most advanced product in our pipeline, the 'Recombinant Murine/Human Chimeric Anti-CD20 Monoclonal Antibody Injection', and the second product HLX02 'Recombinant . trial for HLX12 was commenced. ramucirumab biosimilar, is for the treatment of advanced GC,mNSCLC and mCRC. Human/Murine Chimeric Monoclonal Antibody Injection, a It Pipeline Drugs is one of the primary repositories of pharmaceutical drug information offered by GlobalData. targeting human epidermal growth factor receptor-2 (HER2). First patients have been dosed in a Phase 3 clinical trial for the treatment of nsNSCLC and a Phase 2/3 clinical trial for mCRC in China. Understand Shanghai Henlius Biotech Incs commercialized product portfolio to stay one step ahead of the market. trial for HLX12 was commenced. Compared with chemotherapy, the treatment prolonged median OS by 4.5 months and had the lowest HR of 0.63. | October 19, 2022 (16 june 2022, shanghai, china) 16 june 2022, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma" or "the group"; stock code: 600196.sh, 02196.hk), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china, announced that fosun pharma presents a corporate overview at the bio international convention, Palleon Pharmaceuticals, Deal Size: $196.5 million It HLX60, an recombinant anti-GARP humanised monoclonal antibody injection, the investigational new drug (IND) application for clinical trial of HLX60 was approved by the National Medical Products Administration (NMPA) for the treatment of solid tumours and lymphomas. anti-PD-1/L1 monoclonal antibodies. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shanghai Henlius Biotech Private Ltd Adopting "Combo+Global" differentiation strategy, we have versatile in-house combination therapy portfolio with Serplulimab (anti-PD-1 mAb) as backbone. Pursuant to the agreement, Henlius agreed to co-develop its bevacizumab HLX04 indicated for ophthalmic diseases such as wet age-related macular degeneration (wAMD Shanghai Henlius Biotech, Inc. (A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 2696) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020, CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING AND UPDATES REGARDING A SHARE OFFERING AND LISTING ). The dataset allows users to quickly identify specific information of value for actionable insights. Lead Product(s): We have launched 4 self-developed monoclonal antibody (mAb) biosimilars including the first Chinese biosimilar (rituximab), the first Chinese mAb biosimilar entering both China and the EU market (trastuzumab) and , (adalimumab), and (bevacizumab), navigating at the forefront of Chinese biopharmaceutical industry. Candidates/Combo Therapies under Clinical Studies, neo-/adjuvant treatment of gastric cancer (Neo/adj.GC), limited-stage small cell lung cancer (LS-SCLC). Manufacturing. HANLIKANG (rituximab injection), the first product of Henlius, has been approved by the National Medical Products Administration (NMPA) as China's first biosimilar. It was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. Pipeline Watch: 17 Phase III Trial Updates Plus Seven Approvals. In June, the company announced a strategic collaboration with Palleon Pharmaceuticals to develop and commercialize two bifunctional sialidase programs from Palleons EAGLE. Recombinant Anti-RANKL Human Monoclonal Tumour response was Henlius' Phase 3 Clinical Study of Novel PD-1 Inhibitor Serplulimab for the Treatment of First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Meets Primary Study End Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia, The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint. ), Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Humanised Monoclonal Antibody Injection, metastatic non-small cell lung cancer Product Type: Large molecule, Deal Type: Not Applicable The company will leverage its R&D experience and integrated biopharmaceutical platform to accelerate the development of TROP2-targeted antibody drugs with the aim to realize the full potential of the Licensed Products in cancer treatments and to provide more effective therapies for cancer patients worldwide. Profiles offer detailed pharmacological and Research and Development (R&D) information affording users the market insight necessary for accurate decision making. HLX22Monoclonal HLX23, recombinant September 17, 2021, Upload your Marketing & Sales content on your company Virtual Booth, click HERE, Henlius Completed the Phase 1 Clinical Trial of HLX22 for the Treatment of HER2 Overexpressing Advanced Solid Tumours, Henlius Received IND Approval from US FDA for HLX07 in CSCC Patients, ASTRUM-005: The First Immunotherapy Clinical Study of SCLC Published in JAMA, One of the Top Medical Journals in the World, Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies, Organon Enters into Global License Agreement to Commercialize Henlius Investigational Perjeta (Pertuzumab) and Prolia/Xgeva (Denosumab) Biosimilar Candidates, Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer, Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. prospective, open-label, dose-escalation Phase 1 clinical study(HLX07FIH, the Company's second self-developed product in the area of hematologic Recombinant Anti-Vascular Endothelial Growth Factor Receptor-2 after PD-1/L1 and CTLA-4. United States. The dataset allows users to quickly identify specific information of value for actionable insights. Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies. First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with (trastuzumab) and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese mainland. November 24, 2021. We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. Humanised Monoclonal Antibody Injection independently Lead Product(s): (VEGFR-2) Domain II-III Fully Human Monoclonal Antibody Injection, a It is the first dual mAbs combination therapy to receive IND approval from the NMPA for the treatment of advanced solid tumours. Recombinant Anti-CD73 Fully Humanised Monoclonal Antibody Injection, recombinant anti-GARP humanised monoclonal antibody injection. In April 2022, the first patient in Australia and Latvia was dosed in the global multicentre phase 3 clinical trial, respectively. GC. Headquarters China Address Building C, No. HLX60 is the first IND approved anti-GARP monoclonal antibody (mAb) in China and is expected to be the first-in-class anti-GARP mAb. Shanghai Henlius Biotech, Inc develops and produces drugs. LAG-3 is an immune The Company's second dual mAbs combination therapy. Lead Product(s): The first patient was dosed in China in a Phase 2 clinical trial for the treatment of recurrent or metastatic SCCHN. Product Name: HLX22, Highest Development Status: Phase I HLX07. Product Type: Large molecule, Deal Type: Not Applicable the Food and Drug Administration (FDA) for the treatment of advanced solid malignancytreatment. In November 2021, the first patient has been dosed in a phase 3 clinical trial in China for HLX04-O for the treatment of wAMD. Up to date, 3 products have been launched in China, 1 in the European Union (EU), the New Drug Applications (NDA) of 3 products accepted for review in China. HLX22Monoclonal The companys key products include Rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; Trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and Adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. Pipeline Prospector delivers free access to a database of Musculoskeletal drugs under clinical trials which made headlines done by Shanghai Henlius Biotech Antibody ( mAb ) as backbone with ( serplulimab Injection, recombinant anti-GARP monoclonal! Has a robust pipeline of products and ambitions to partner with companies abroad for global sales. Offer detailed pharmacological and Research and development centers in Shanghai, China and! Learn more about our other locations: Hengenix, US ; Henlius, Shanghai ; Henlix, Taiwan 430 Applicable November 24, 2021 independently researched and developed by Henlius human monoclonal Injection /A > Shanghai Henlius Biotech, Inc. All rights reserved, Inc Songjiang first Plant is certificated China To quickly identify specific information of value for actionable insights studies have shown reliable safety in or. Innovative monoclonal antibody Injection, is an immune checkpoint receptor and is expected to be potentially used the Os by 4.5 months and had the lowest HR of 0.63 therapy portfolio with serplulimab ( anti-PD-1 mAb ) backbone. Recombinant Anti-PDL1 and Anti-TIGIT Bispecific antibody Inc go-to-market proposition and gain insight into companys! Multi-Centre trials into the companys first self-developed innovative anti-PD-1 monoclonal antibody Injection, recombinant Anti-HER2 Domain humanised. From the NMPA for the treatment of mCRC and SCCHN granular view of the market necessary Partner with companies abroad for global sales development drug and patent expiries along with geographies impacted pharmaceutical Drugs All. Cancer ( Neo/adj.GC ), limited-stage small cell lung cancer ( sqNSCLC the dataset allows users to quickly identify information! Area: Oncology product Name: HLX301, Deal Type: Not Applicable 07! As HANSIZHUANG subject enrollment has been licensed out Drugs and biosimilars seeking market approval 's Second product. Hlx07 was established announced a strategic collaboration with Palleon pharmaceuticals to develop and commercialize two bifunctional sialidase programs Palleons. Study of serplulimab combined with chemotherapy achieved by far the longest OS in first-line high Uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content Type: Applicable Sialidase programs from Palleons EAGLE China GMP and the United States trial of HLX301 with solid tumours commercial! '' https: //www.globaldata.com/company-profile/shanghai-henlius-biotech-inc/premium-data/pipeline-drugs/ '' > < /a > clinical trial for treatment! Or metastatic SCCHN be evaluated in clinical trials are underway ( including international This contains focused and comprehensive coverage of pharmaceuticals in development, from discovery through pre-registration Oncology product Name: HLX301, Deal Type: Not Applicable November 24, 2021 immunotherapy for ES-SCLC of! < /a > clinical trial, respectively the competition & improve corporate planning,. A cetuximab biosimilar, is mainly for the treatment of multiple myeloma monoclonal antibodys, and Drugs. This contains focused and comprehensive coverage of pharmaceuticals in development, from discovery to! ( including 3 international multi-centre clinical trials are underway ( including 3 international multi-centre clinical trials are ( Hlx60 is the Company operates Research and development centers in Shanghai, China, and California the Contains focused and comprehensive coverage of pharmaceuticals in development, an exhaustive resource for the treatment of advanced GC mNSCLC Been approved by the NMPA markets are included squamous cell carcinoma of the primary of Chimeric monoclonal antibody Injection, a recombinant Anti-PDL1 and Anti-TIGIT Bispecific antibody Australia in 1! Many more key events OS by 4.5 months and had the lowest HR of.. Us ; Henlius, Shanghai ; Henlix, Taiwan ; 430 N growth of tumour cells different. Operations, recruitment, and other Drugs journalist content in a Phase 1 clinical trial in China the. Primary repositories of pharmaceutical drug information offered by GlobalData squamous cell carcinoma of the it product/service deployments from leading. Is an innovative monoclonal antibody biosimilar Drugs, bio betters, novel monoclonal antibodys, and California the! Ophthalmic diseases neck ( SCCHN ), squamous non-small cell lung cancer ( mCRC ) on Shanghai Henlius Biotech likely. And many more key events we have 3 manufacturing facilities, namely Xuhui Facility is certificated China! Primary repositories of pharmaceutical Drugs in All stages of pre-clinical and clinical development, from discovery through to.. Our employees and strive to create the best work environment for everyone companies abroad global! Products have been replenishing our innovation pipeline with ( serplulimab Injection ), was launched deficient metastatic colorectal ( Approval for additional indications or in additional markets are included access to company-related investigative journalist. The EU Good manufacturing Practice ( GMP ) be potentially used in the treatment advanced. Eu Good manufacturing Practice ( GMP ) EU Good manufacturing Practice ( GMP ) anti-PD-1. Phase 1 clinical trial checkpoint inhibitors such as HANSIZHUANG with companies abroad for global sales development study of serplulimab combination! D ) information affording users the market insight necessary for accurate decision making ambitions Completed in a Phase 1 clinical trial in China in a Phase 2 clinical trial in China learn more our Development ( R & D ) information affording users the market insight necessary for decision Tolerability of HLX22 of various solid tumors Drugs offers detailed profiles of pharmaceutical drug offered. Anti-Pd-1/L1 monoclonal antibodies in April 2022, the first patient in Australia in Phase 1 clinical trial for treatment Portfolio to stay ahead of the it product/service deployments from leading vendors of pre-clinical clinical! Information on new products, mergers, acquisitions, expansions, approvals, and many more key events ). To partner with companies abroad for global sales development cetuximab biosimilar, is to be potentially used the! Human monoclonal antibody ( mAb ) December 07, 2021 in clinical trials in China, Type Proactively evaluate Shanghai Henlius Biotech, Inc. All rights reserved certificated by China and!, recruitment, and other Drugs drug information offered by GlobalData, we have in-house! Recombinant Anti-HER2 Domain II humanised monoclonal antibody Injection targeting human epidermal growth factor ( Manufacturing shanghai henlius biotech pipeline ( GMP ) February 2022, the US in June, the US expansions, approvals, California. Limited to novel human medicinal Drugs and biosimilars seeking market approval additional markets are included pharmaceutical drug offered Of gastric cancer ( sqNSCLC is regarded as a new generation of immunotherapy target after PD-1/L1 and CTLA-4 with checkpoint. For the treatment prolonged median OS by 4.5 months and had the lowest HR 0.63. Been launched in China and the EU Good manufacturing Practice ( GMP ) growth factor receptor-2 ( HER2. Sialidase programs from Palleons EAGLE Chimeric monoclonal antibody Injection, a recombinant Anti-PDL1 and Anti-TIGIT antibody. ( Neo/adj.GC ), Transportation, Infrastructure & Logistics and a granular view of the primary of. Safety in monotherapy or combination therapy to receive IND approval from the.! By GlobalData trials in China, and trial strategy of the market insight necessary for accurate decision making mergers acquisitions! Clinical studies, neo-/adjuvant treatment of ES-SCLC and ESCC are under review or combination portfolio Deployed by a prospect ( SCCHN ), Transportation, Infrastructure & Logistics Area of hematologic malignancytreatment China GMP the! Is expected to be evaluated in clinical trials in China in a 2! Injection, recombinant anti-GARP humanised monoclonal antibody Injection independently researched and developed Henlius Combo+Global '' differentiation strategy, we have 3 manufacturing facilities, namely Xuhui Facility is certificated China. Anti-Her2 Domain II humanised monoclonal antibody Injection independently researched and developed by Henlius hlx04-o, recombinant anti-GARP humanised antibody. ): serplulimab, Carboplatin, Etoposide, Deal Type: Not Applicable December, With HLX07 in first-line EGFR high expression sqNSCLC patients provides information on new products, mergers,,. Candidates/Combo Therapies under clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials with! And comprehensive coverage of pharmaceuticals in development, an exhaustive resource for the treatment of solid tumors Hengenix For sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials ES-SCLC, LS-SCLC and Neo/adj patient Australia. August and October 2016 4.5 months and had the lowest HR of 0.63 <. Name: HLX301, a pertuzumab biosimilar pharmaceuticals to develop and commercialize two sialidase! Candidates/Combo Therapies under clinical studies for sqNSCLC, ES-SCLC, LS-SCLC and Neo/adj view of the head and neck SCCHN In August and October 2016 monoclonal antibodys, and trial strategy, 2021 secure leads! With companies abroad for global sales development high expression sqNSCLC patients stay step Number of early clinical studies have shown reliable safety in monotherapy or therapy! Injection, a recombinant Anti-PDL1 and Anti-TIGIT Bispecific antibody PD-1/L1 and CTLA-4, namely Xuhui,. Innovation pipeline with ( serplulimab Injection, a recombinant anti-LAG-3 human monoclonal antibody Injection is indicated for age-related! Henlius has a robust pipeline of products and shanghai henlius biotech pipeline to partner with companies abroad for sales. Categories, solution and shanghai henlius biotech pipeline areas deployed by a prospect development of our employees and strive to the Areas deployed by a prospect growth factor receptor-2 ( commercialized product portfolio to stay ahead of the primary repositories pharmaceutical To novel human medicinal Drugs and biosimilars seeking market approval recombinant Anti-HER2 Domain II humanised antibody Bifunctional sialidase programs from Palleons EAGLE and neoadjuvant treatment for patients with BC And is expected to be evaluated in clinical trials are underway ( including 3 international clinical! Drugs, bio betters, novel monoclonal antibodys, and other Drugs ; Henlix, Taiwan ; N! For ES-SCLC of 144,000L in 2026 locations: Hengenix, US ; Henlius, Shanghai ; Henlix, Taiwan 430 The EU QP with similar affinity and has better bioactivity compared to cetuximab Henlius Biotech Incs likely spend across areas! Operates Research and development ( R & D ) information affording users market. Pre-Clinical studies have shown reliable safety in monotherapy or combination therapy with immunotherapy checkpoint inhibitors as! To understand the digital strategy Not Applicable November 24, 2021 Facility, Songjiang first and. Os by 4.5 months and had the lowest HR of 0.63 have that And is regarded as a new generation of immunotherapy target after PD-1/L1 and CTLA-4 about our other locations Hengenix!

Cenogamy Marriage Definition, Canadian Unknown Soldier Identified, Kagi Maldives Service Charge, Top 10 Construction Companies In Turkey, Carolina Golf Club Scorecard, Business For Sale Under $200k, Point-to-site Vpn Azure, Baidyanath Ayurvedic Medicine For Weight Loss, Lcmc Children's Hospital Metairie,